Tag Archives: ONTY

No Comments

CBOE Mid-Day Update 6.1.15

Volatility as an asset class Oncothyreon Inc. (ONTY) is recently up 60c to $4.03 after announcing positive data from the company’s ongoing trials of ONT-380, an orally active, reversible and selective small-molecule HER2 inhibitor for the treatment of breast cancer, at the American Society of Clinical Oncology (ASCO) 2015 Annual Meeting.  June call option implied […]